• Username (E-mail)
  • Password
Dow 19,805 -0.1%  EStoxx50 3,294 0.3%  Nikkei 19,072 0.9%  EUR 1.0638 0.1% 
Nasdaq 5,556 0.3%  FTSE100 7,248 0.4%  Yen 114.6090 0.1%  Oil 54.4 0.3% 
S&P500 2,272 0.2%  DAX 11,599 0.5%  GBP 1.2279 0.1%  Gold 1,202 -1.5% 

Vertex Pharmaceuticals share [Symbol: VRTX / ISIN: US92532F1003]

12/05/2012 07:59:30 AM
12/05/2012 07:59:30 AM UTC-0500

Vertex Pharmaceuticals Inc. Outperform

The analysts of RBC Capital Markets have rated Vertex Pharmaceuticals with a Outperform rating. The price target was set to 70.00 $. At a current price of the Vertex Pharmaceuticals stock of 82.49 $ this means a downside potential of -15.14%.
Summary: Vertex Pharmaceuticals Inc. Outperform
Company:
Vertex Pharmaceuticals Inc.
Analyst:
RBC Capital Markets
Price Target:
70.00 $
Current Rating:
Outperform
Price*:
39.21 $
Distance to Target Price*:
78.53%
Previous Rating:
n/A
Latest Price:
82.49 $
Distance Price Target:
-15.14%
Analyst Name::
Charmaine Chan
P/E Ratio*:
-

Analyst Opinions for Vertex Pharmaceuticals Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
12/14/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
12/05/12
Vertex Pharmaceuticals RBC Capital Markets
11/13/12
Vertex Pharmaceuticals Credit Suisse Group
11/05/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
11/02/12
Vertex Pharmaceuticals UBS AG

Add or Edit Instrument

Related Stocks

Latest Analyst Opinions
01/18/17 ABB Citigroup Corp.
01/18/17 Siemens Citigroup Corp.
01/18/17 PUMA Commerzbank AG
01/18/17 HSBC Morgan Stanley
01/18/17 Alstom Morgan Stanley
01/18/17 Deutsche Euroshop DZ BANK
01/18/17 Pfizer Goldman Sachs Group Inc.
01/18/17 McDonalds Nomura
01/18/17 Volvo (B) Morgan Stanley
01/18/17 Deutsche Telekom Bernstein Research
01/18/17 Bayer Kepler Cheuvreux
01/18/17 Jungheinrich Kepler Cheuvreux
01/18/17 SAF-Holland Kepler Cheuvreux
01/18/17 Credit Suisse UBS AG
01/18/17 ING Group UBS AG
01/18/17 Sky UBS AG
01/18/17 Vodafone Group UBS AG
01/18/17 Essilor International UBS AG
01/18/17 Telefonica UBS AG
01/18/17 Orange UBS AG
01/18/17 Lloyds Banking Group UBS AG
01/18/17 Software Baader Bank
01/18/17 Nemetschek Baader Bank
01/18/17 Deutsche Euroshop Baader Bank
01/18/17 CTS Eventim Baader Bank
01/18/17 British American Tobacco Citigroup Corp.
01/18/17 Fresenius Citigroup Corp.
01/18/17 Volvo (B) Jefferies & Company Inc.
01/18/17 Adler Real Estate DZ BANK
01/18/17 SAF-Holland Hauck & Aufhäuser Privatbankiers KGaA
01/18/17 Hella JP Morgan Chase & Co.
01/18/17 Axel Springer DZ BANK
01/18/17 Essilor International Goldman Sachs Group Inc.
01/18/17 RATIONAL Independent Research GmbH
01/18/17 Apple Goldman Sachs Group Inc.
01/18/17 Beiersdorf Goldman Sachs Group Inc.
01/18/17 Diageo Jefferies & Company Inc.
01/18/17 BP Goldman Sachs Group Inc.
01/18/17 Deutsche Lufthansa Independent Research GmbH
01/18/17 TOTAL Goldman Sachs Group Inc.
01/18/17 Eni Goldman Sachs Group Inc.
01/18/17 Hannover Rueck JP Morgan Chase & Co.
01/18/17 Alstom Goldman Sachs Group Inc.
01/18/17 Münchener Rückversicherungs-Gesellschaft JP Morgan Chase & Co.
01/18/17 Walt Disney Goldman Sachs Group Inc.
01/18/17 Anheuser-Busch InBev Jefferies & Company Inc.
01/18/17 Beiersdorf JP Morgan Chase & Co.
01/18/17 Zalando JP Morgan Chase & Co.
01/18/17 BT Group Jefferies & Company Inc.
01/18/17 Swiss Re Jefferies & Company Inc.